NCT04231084View on ClinicalTrials.gov

Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

PHASE4CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2024

Conditions
Pulmonary Hypertension
Interventions
DRUG

Vasodilator testing (Inhaled Nitric Oxide)

Right heart catheterization with vasodilator testing with each arms' associated agent will be performed

DRUG

Vasodilator testing (Inhaled Epoprostenol)

Right heart catheterization with vasodilator testing with each arms' associated agent will be performed

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT04231084 - Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide | Biotech Hunter | Biotech Hunter